Literature DB >> 9662764

Rates of and risk factors for trichomoniasis among pregnant inmates in New York City.

J Shuter1, D Bell, D Graham, K A Holbrook, E Y Bellin.   

Abstract

BACKGROUND: Trichomonas vaginalis is a common pathogen that is associated with adverse pregnancy outcomes and may serve as a cofactor in human immunodeficiency virus (HIV) transmission. GOAL: To define the epidemiology of trichomoniasis in a population of newly incarcerated pregnant women in New York City. STUDY
DESIGN: Prospective study of 213 pregnant prisoners attending prenatal clinic. Patients participated in an interview regarding sexual and drug-related behaviors, and underwent direct culture for T. vaginalis in addition to routine testing for syphilis, gonorrhea, and chlamydia.
RESULTS: The prevalence of trichomoniasis was 46.9%. On univariate analysis, there was a significant association between trichomoniasis and older age, crack use, prostitution, known HIV infection, and positive serological test for syphilis. Multivariate analysis showed a significant association of trichomoniasis with crack use and positive serological test for syphilis.
CONCLUSION: Trichomoniasis is highly prevalent in pregnant prisoners in New York City. The extent of disease observed may justify a formal program of testing and treatment and emphasizes the urgent need for harm reduction education and expanded HIV counseling and testing services in this high-risk population.

Entities:  

Mesh:

Year:  1998        PMID: 9662764     DOI: 10.1097/00007435-199807000-00006

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  23 in total

1.  Predictors of infection with Trichomonas vaginalis: a prospective study of low income African-American adolescent females.

Authors:  R Crosby; R J DiClemente; G M Wingood; K Harrington; S L Davies; E W Hook; M K Oh
Journal:  Sex Transm Infect       Date:  2002-10       Impact factor: 3.519

2.  Risk and prevalence of treatable sexually transmitted diseases at a Birmingham substance abuse treatment facility.

Authors:  L H Bachmann; I Lewis; R Allen; J R Schwebke; L C Leviton; H A Siegal; E W Hook
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

3.  Incidence of sexually transmitted infections among hazardously drinking women after incarceration.

Authors:  Michael D Stein; Celeste M Caviness; Bradley J Anderson
Journal:  Womens Health Issues       Date:  2011-08-10

4.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

5.  Characterizing medical providers for jail inmates in New York State.

Authors:  Noga Shalev; Mary Ann Chiasson; Jay F Dobkin; Gunjeong Lee
Journal:  Am J Public Health       Date:  2011-02-17       Impact factor: 9.308

6.  A Trich-y question: should Trichomonas vaginalis infection be reportable?

Authors:  Brooke E Hoots; Thomas A Peterman; Elizabeth A Torrone; Hillard Weinstock; Elissa Meites; Gail A Bolan
Journal:  Sex Transm Dis       Date:  2013-02       Impact factor: 2.830

7.  Epidemiology and treatment of trichomoniasis.

Authors:  Patricia Kissinger
Journal:  Curr Infect Dis Rep       Date:  2015-06       Impact factor: 3.725

Review 8.  Trichomonas vaginalis, HIV, and African-Americans.

Authors:  F Sorvillo; L Smith; P Kerndt; L Ash
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

9.  A service evaluation of the Gen-Probe APTIMA nucleic acid amplification test for Trichomonas vaginalis: should it change whom we screen for infection?

Authors:  Emma Hathorn; Andrea Ng; Matthew Page; James Hodson; Charlotte Gaydos; Jonathan D C Ross
Journal:  Sex Transm Infect       Date:  2014-08-28       Impact factor: 3.519

Review 10.  Current issues and considerations regarding trichomoniasis and human immunodeficiency virus in African-Americans.

Authors:  Shira C Shafir; Frank J Sorvillo; Lisa Smith
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.